# A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

Source: https://onco.cc/trials/nct05615974/  
OnCo record `nct05615974` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Toripalimab and Rituximab in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.

## Summary

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT05615974 by LaNova Medicines Limited, with 139 participants planned, started 2023-01-11 and due to reach its primary completion in 2027-01-11. Interventions recorded: LM101, Toripalimab and Rituximab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05615974
- Phase: 1/2
- Setting: A Phase I/II, Open-label, Dose Escalation, and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of LM-101 Injection as a Single Agent or Combination Therapy in Patients With Advanced Malignant Tumors
- Sponsor: LaNova Medicines Limited
- Enrolled: 139

## Sources

- ClinicalTrials.gov NCT05615974: https://clinicaltrials.gov/study/NCT05615974

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Rituximab](https://onco.cc/drugs/rituximab/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- companies: [LaNova Medicines](https://onco.cc/companies/lanova-medicines/)

---
JSON: https://onco.cc/api/v1/entities/nct05615974.json